Artis BioSolutions Establishes U.S.-based Synthetic DNA Manufacturing Hub in Boston

Expanded facility integrates Syngoi Technologies’ enzymatic DNA platform into Artis’ North American operations, ensuring resilient, U.S.-based, clinical-grade supply chains for advanced therapies

SAN DIEGO & WATERTOWN, Mass.--(BUSINESS WIRE)--Artis BioSolutions (“Artis”), an advanced therapies company dedicated to integrating the specialized technologies, infrastructure, and manufacturing capabilities required to deliver next-generation genetic medicines, today announced the establishment of new synthetic DNA manufacturing capabilities in Boston utilizing Syngoi Technologies’ (“Syngoi”) proprietary enzymatic platform. This expansion strategically extends Artis’ regional capabilities, integrating with its advanced therapy development and GMP manufacturing facility in Watertown, MA, to deliver reliable, scalable, and efficient solutions for its global customer base.

“Artis was founded to more effectively provide platforms and capabilities that drug developers require to bring next-generation medicines to patients,” said Brian Neel, CEO of Artis. “Establishing U.S.-based synthetic DNA manufacturing is a pivotal step in the evolution of the Artis platform and reinforces our mission to integrate specialized technologies — from synthetic DNA through GMP manufacturing — into a seamless, end-to-end offering. By offering Syngoi Technologies at our U.S. site, we are delivering a much needed capability to our customers focused on early development through clinical manufacturing while strengthening our global operational resilience.”

By operating production hubs on both sides of the Atlantic, Artis provides enhanced service continuity and a more secure supply chain for its global partners. This dual-sourcing strategy across the U.S. and Europe reduces lead times and logistics costs while mitigating the geopolitical and operational risks associated with single-region sourcing. The expansion also positions Artis’ specialized technical expertise in immediate proximity to its key clients and strategic partners in the U.S. market.

“From our beginning, Syngoi set out to reimagine how clinical-grade synthetic DNA is produced and delivered for advanced therapy applications,” said Julen Oyarzabal, CSO of Syngoi.

“Establishing this new U.S.-based manufacturing site is a natural extension of that mission. Operating in the premier biotechnology innovation ecosystem of the greater Boston area, allows us to respond more rapidly to regional customer demand while maintaining the continuity and technical excellence of our European operations,” said José Vicente Pons Andreu, CEO of Syngoi.

Syngoi’s proprietary enzymatic platform enables the rapid production of clinical-grade synthetic DNA through a cell-free cGMP process. By replacing traditional plasmid-based bacterial fermentation with an enzymatic approach, Syngoi provides a more predictable, high-purity supply of genetic material with significantly reduced lead times. By utilizing a proprietary library of adaptors and a multifactorial approach, Syngoi can manufacture custom, project-optimized DNA with unique features tailored to each specific program.

About Artis BioSolutions

Artis BioSolutions is a San Diego–based advanced therapies platform focused on developing and scaling the technologies, infrastructure, and capabilities required to enable next-generation medicines. The company combines proprietary and enabling technologies with specialized expertise across development and manufacturing to support biotechnology and pharmaceutical innovators advancing emerging therapeutic modalities. Their Watertown, MA site combines process development, advanced analytics, and GMP manufacturing. Learn more at artisbiosolutions.com.

About Syngoi Technologies

Syngoi Technologies is a biotechnology company based in Bilbao, Spain, focused on innovative synthetic DNA technologies for use in advanced therapies. The company has developed a differentiated platform designed to improve how DNA inputs are produced and supplied, supporting emerging therapeutic modalities and next-generation manufacturing approaches. Learn more at: syngoi.com.